Prof. Dr. Hong Liang
Tel: + 86- (0)773- 2120958或+ 86- (0)773- 3560088
E-mail: hliang@gxnu.edu.cn
Prof. Dr. Hong Liang is currently the vice chairman of Guangxi Association for Science and Technology, director of the State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education, and a supervisor for Ph. D program in Guangxi Normal University, Ph.D programs of Inorganic Chemistry in Nankai University and Nanjing University, and Ph.D program of Applied Chemistry in Central South University. He served as the president of Guangxi Normal University from Jan. 2002 to July 2017.
Prof. HongLiang has devoted himself to Chemistry research and teaching in western Chinasince he got his doctoral degree in Nankai University in 1991. In scientificresearch, he has so far ledmore than 30 projects and programs, including one Key NationalNatural Science Fund Project, three 973 pre-special programs, and seven National Natural ScienceFund Projects. Among over 500papers he published in the SCI key journals like PNAS, Nat. Commun., ACIE, JACS,Adv. Sci.,ACS Nano, Coord. Chem. Rev., J. Med. Chem.,APSB, Small, Eur.J.Med. Chem.,Mol. Pharm., Inorg.Chem.,Anal. Chem., J. Inorg. Biochem.,CCS Chem., andhis papers have been cited for over 13800 times in SCI journals, and H-index is 60.Furthermore, he has possessed more than 60 authorized invention patents inChina. For his outstanding academic achievements, he was awarded quite a few prizes and honorarytitles, such as, Fellow of Royal Society of Chemistry(FRSC), Editorial BoardMember for Journal of Inorganic Biochemistry(JIB)，Journal of Natural Medicines Research(JNMR), Fellow ofChinese Chemical Society(FCCS),and so on..
For over30 years, Prof. Liang has taken up a systematic and innovational research inthe field of Inorganic Biochemistry and Inorganic Medicinal Chemistry, makingthree important contributions to development of Chinese Inorganic Chemistry including(1) Opening up the new research field of TCMAI-based (Traditional Chinese medicine’s active ingredient) inorganic medicinalchemistry;(2) Enriching and expanding the field of HSA-based inorganicbiochemistry;(3) Making a high achievement in the field of bio-nano-materialchemistry and life analytical chemistry.
Research Interests
1. Pharmacological effects of active components of traditional Chinese medicine in metal-based anti-tumor drugs
2. Novel metal-based anti-tumor drugs and drug delivery system of protein
1）Mechanism of cell migration
2）DNA and Protein based design of novel metal-based anti-tumor drugs
3）Protein nanoparticle drug delivery system
3. Integration of diagnosis and treatment of nanoparticle materials
4. New method of real-time in-situ monitoring of life process
Social service
1.Fellow of Royal Society of Chemistry, UK
2.Director of Chinese chemistry Association
3. Member of Inorganic Chemistry Committee of Chinese chemistry Association
4. Member of Applied Chemistry Committee of Chinese chemistry Association
5.Honorary director of Chemistry and Chemical Industry Society of Guangxi
6.Guest editor for Curr Pharm Des
7. Member of editorial board for Journal of Inorganic Biochemistry, Chinese Journal of Inorganic Chemistry, Journal of Chemistry Education
Course
Bioinorganic Chemistry
Recent Publications and Patents
Articles
1. Ke-Bin Huang, Feng-Yang Wang, Yuan Lu, Liang-Mei Yang, Nian Long, Shan-Shan Wang,Zhiying Xie, Matthew Levinec, Taotao Zou*, Jonathan L. Sessler*, Hong Liang*. Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response bytargeting cellularredox homeostasis. PNAS, 2024, 121(24), e2404668121.
2. XueyuMan , Wenjuan Li , Minghui Zhu , Shanhe Li , Gang Xu , Zhenlei Zhang , HongLiang*, Feng Yang*. Anticancer Tetranuclear Cu(I) Complex Catalyzes a ClickReaction to Synthesize a Chemotherapeutic Agent in situ to Achieve Targeted Dual-Agent Combination Therapy for Cancer. Angew. Chem. Int. Ed., 2024 DOI: 10.1002/anie.202411846.
3. PeijingXu, Changchun Wen, Cunji Gao*, Huihui Liu, Yingshu Li, Xiaolu Guo, Xing-CanShen*, Hong Liang*. Near-Infrared-II-Activatable Self-Assembled ManganesePorphyrin-Gold Heterostructures for Photoacoustic Imaging-Guided Sonodynamic-Augmented Photothermal/Photodynamic Therapy. ACS Nano, 2024, 18,713−727.
4. YuanLu, Shan-Shan Wang, Meng-Ya Li, Rong Liu, Meng-Fan Zhu, Liang-Mei Yang,Feng-Yang Wang, Ke-Bin Huang*, Hong Liang*. Cyclometalated iridium(III) complexbased on isoquinoline alkaloid synergistically elicits the ICD response and IDOinhibition via autophagy-dependent ferroptosis. Acta Pharm. Sin. B, 2024, DOI: 10.1016/j.apsb.2024.06.017.
5. YulongBai, Jing Hua, Jingjin Zhao*, Shulong Wang, Mengjiao Huang, Yang Wang, YanniLuo, Shulin Zhao*, Hong Liang*. A Silver-Induced Absorption Red-ShiftedDual-Targeted Nanodiagnosis-Treatment Agent for NIR-II PhotoacousticImaging-Guided Photothermal and ROS Simultaneously Enhanced Immune Checkpoint Blockade Antitumor Therapy. Adv. Sci., 2023, 2306375.
6. Qi-Yuan Yang+, Rui Ma+,Yun-Qiong Gu+, Xiao-Fang Xu, Zhen-Feng Chen*, Hong Liang*. Arene-Ruthenium(II)/Osmium(II) Complexes Potentiate the Anticancer Efficacy of Metformin via Glucose Metabolism Reprogramming. Angew. Chem. Int. Ed., 2022, e202208570.
7. Xiaolin XiongⅡ, Ke-Bin HuangⅡ, Yuan WangⅡ, Bei Cao, Yunli Luo, Huowen Chen, Yan Yang, Yan Long, MoyiLiu, Albert S. C. Chan, Hong Liang*, Taotao Zou*. Target Profiling of anIridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP. J. Am. Chem. Soc., 2022,144, 23, 10407–10416.
8. Yan-Lei Ma*, Ji-Ping Yue*, Yao Zhang*, Chen-Zhang Shi*,Matt Odenwald, Wenguang G. Liang, Qing Wei, Ajay Goel, Xue-Wen Gou, JamieZhang, Shao-Yu Chen, Wei-Jen Tang, Jerrold R. Turner, Feng Yang, Hong Liang*, Huan-Long Qin, Xiao-YangWu. ACF7 regulates inflammatory colitis and intestinal wound response byorchestrating tight junction dynamics. Nat. Commun. 2017,8, 15375.
9. Ji-Ping Yue, Yao Zhang, Wen-Guang G. Liang, Xue-Wen Gou,Philbert Lee, Han Liu, Wan-Qing Lyu, Wei-Jen Tang, Shao-Yu Chen, Feng Yang*, Hong Liang*, Xiao-Yang Wu*. InVivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nat.Commun. 2016, 7, 11692.
10. Yi Gou, GuoJin Huang , Jinlong Li, Feng Yang*, Hong Liang*. Versatile delivery systemsfor non-platinum metal-based anticancer therapeutic agents, Coordin.Chem. Rev., 2021, 441, 213975.
11. Wenjuan Li, Shanhe Li, Zhenlei Zhang, GangXu, Xueyu Man, Feng Yang*, Hong Liang*. Developing a Multitargeted AnticancerPalladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin. J. Med. Chem., 2023, 66, 8564–8579.
12. XingLu, Mei-Feng Wu, Jiang-Lun Wu, Hai-Qun Zhang, HongLiang*, Zhen-Feng Chen*. Platinum-Based Mcl‑1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity asa Single Agent or in Combination withABT-199.J. Med. Chem., 2023, 66, 8705−8716.
13. ZhenleiZhang†, Juzheng Zhang†, Tongfu Yang†, Shanhe Li, Gang Xu, Hong Liang*,Feng Yang*. Developing an Anticancer Platinum(II) Compound Based on theUniqueness of Human Serum Albumin. J. Med. Chem., 2023,66，5669−5684.
14. XueyuMan§, Tongfu Yang§, Wenjuan Li, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang*,Feng Yang*. Developing a Gadolinium(III) Compound Based on Apoferritin forTargeted Magnetic Resonance Imaging and Dual-Modal Therapy of Cancer. J. Med. Chem., 2023,66, 7268−7279.
15. TongfuYang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang*,Feng Yang*. Developing a Gallium(III) Agent Based on the Properties of theTumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery andMulti-targeted Combination Therapy of Cancer. J. Med. Chem., 2023,66，793−803.
16. Shuang Kan, Rong Li, Yanhui Tan, Fang Yang, Shaohua Xu, Lingzhu Wang, Lijun Zhang, Xuchen Sun, Xuanming Chen, Yuting Yang, Wei Shu, Huaibin Wan, Zheng-Feng Chen, Hong Liang*, Ming Chen*. Latexin deficiency attenuates adipocyte differentiation and protects miceagainst obesity and metabolic disorders induced by high-fat diet. Cell Death & Disease,2022,13(2):175 .
17. Wen-Ying Shen, Chun-Peng Jia, Li-YiLiao,Liu-Lin Chen, Cheng Hou, Yang-Han Liu, Hong Liang*, Zhen-Feng Chen*. Copper(II) Complexes ofHalogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy throughGlutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux. J. Med. Chem., 2022, 65,5134-5148.
18. Ming Jiang, Yong Chu, Tongfu Yang, WenjuanLi, Zhenlei Zhang, Hongbin Sun, HongLiang*, Feng Yang*. Developing a Novel Indium(III) AgentBased on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer byMultitargeting the Tumor Microenvironment Components. J. Med. Chem.,2021,64, 14587–14602.
19. ShulongWang, Jingjin Zhao, Liangliang Zhang*, Chaobang Zhang, Zhidong Qiu, Shulin Zhao*. Yong Huang, Hong Liang*. A Unique MultifunctionalNanoenzyme Tailored for Triggering Tumor Microenvironment Activated NIR-IIPhotoacoustic Imaging and Chemodynamic/Photothermal Combined Therapy. Adv. Healthcare Mater.,2021,2102073.
20. Juzheng Zhang, Ming Jiang, Shanhe Li, Zhenlei Zhang, Hongbin Sun, Feng Yang*, Hong Liang*. Developing a NovelAnticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. J. Med. Chem., 2021, 64, 6777–6791.
21. Ju-Zheng Zhang, Zhen-Lei Zhang, MingJiang, Shan-He Li, Hao-Liang Yuan, Hong-Bin Sun, Feng Yang*, Hong Liang*. Developing a novelgold(III) agent to treat glioma based on the unique properties of apoferritinnanoparticles: inducing lethal autophagy and apoptosis，J. Med. Chem., 2020, 63, 13695–13708.
22. Noor Shad Gul†, Taj-MalookKhan1†, Yan-Cheng Liu, Muhammad Iqbal Choudhary, Zhen-Feng Chen*, HongLiang*. Pd(II) and Rh(III) Complexes with Isoquinoline DerivativesInduced Mitochondria-Mediated Apoptotic and Autophagic Cell Death in HepG2Cells, CCS Chem., 2020, 2, 1626–1641.
23. Xing Lu, Yan-Cheng Liu, Chris Orvig, HongLiang*, Zhen-Feng Chen*. Discovery of aCopper-Based Mcl‑1 Inhibitor as an Effffective Antitumor Agent, J. Med.Chem., 2020, 63, 9154–9167.
24. Zhen-Lei Zhang, Ping Yu, Yi Gou,Ju-Zheng Zhang, Shan-He Li, Mei-Ling Cai, Hong-Bin Sun, Feng Yang*, HongLiang*. A novel brain-tumor-inhibitingcopper(II) compound based on HSA–cell penetrating peptide conjugate. J. Med. Chem., 2019, 62, 10630–13069.
25. Ke-Bin Huang, Feng-Yang Wang, Xiao-Ming Tang, Hai-WenFeng, Zhen-Feng Chen*, Yan-Cheng Liu, You-Nian Liu, Hong Liang*. Organometallic Gold(III) Complexes Similar to TetrahydroisoquinolineInduce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 CancerCells.J. Med. Chem.,2018,61, 3478-3490.
26. Bang-Ping Jiang, Li Zhang, Xiao-Lu Guo,Xing-Can Shen*, Yan Wang, Yang Zhu,HongLiang*. Poly(N-phenylglycine)-Based Nanoparticles as HighlyEffective and Targeted Near-Infrared Photothermal Therapy/PhotodynamicTherapeutic Agents for Malignant Melanoma. Small,2017, 13, 1602496.
27. Zhen-FengChen*, Qi-Pin Qin, Jiao-Lan Qin, Jie Zhou, Yu-Lan Li, Nan Li, Yan-Cheng Liu, Hong Liang*.Water-soluble ruthenium(II) complexes with chiral4-(2,3-Dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivoanticancer activity by stabilization of G-Quadruplex DNA, inhibition oftelomerase activity, and induction of tumor cell apoptosis. J. Med. Chem. 2015, 58, 4771–4789.
28. Zhen-FengChen*, Qi-Pin Qin, Jiao-Lan Qin, Yan-Cheng Liu, Ke-Bin Huang, Yu-Lan Li, TingMeng, Guo-Hai Zhang, Yan Peng, Xu-Jian Luo, Hong Liang*. Stabilization of G-quadruplex DNA, inhibition oftelomerase activity, and tumor cell apoptosis by organoplatinum(II) complexeswith oxoisoaporphine. J. Med. Chem.,2015, 58, 2159–2179.
29. Ming-HuaZeng*,Min-XiaYao, Hong Liang*, Wei-XiongZhang, Xiao-MingChen. A Single-Molecule-Magnetic, Cubane-Based, Triangular Co12Supercluster. Angew. Chem. Int. Ed., 2007, 46, 1832–1835.
30. Yi Gou*, Li Liu, Hong Liang*. Editorial on the Research Topic: The Developments of Metal-Based Agents Against Lung Cancer. Front Pharmacol., 2022,13, https://doi.org/10.3389/fphar.2022.1101890.
Research Projects
1. Training Project for Candidatesfor the Academician of the Chinese Academy of Engineering (1500万元, 2017.1-2021.12)
2.National Natural Science Foundation of China（Major Program）:Developing Metal-based Anti-tumor Complexes from Active Components of Traditional Chinese Medicine (360万元, 2015.1-2019.12)
3. Project of Plan 973: A Research on Developing Metal-based Anti-tumor Complexes from Active Components of Traditional Chinese Medicine and Chemical Assembly and Activity Evaluation onNatural Cyclic Peptide Potential Drugs(255万元, 2012-2015)
4. Innovative Teams Project of Ministry of Education of China (Academic Leader, rank No.2) : (450万元, 2013-2016 ; 300万元, 2017-2019滚动）
5. National Natural Science Foundation of China No. 21171043: A Research on the Interaction Among Anti-tumor Phytomedicines, Metal-based Drugs and Human Serum Albumin(80万元, 2012.1-2015.12)
Titles
1. Leading Talent of National “Ten-thousand Talents Program” 2016
2. Firstly Selected Candidates from Guangxi for the Academician of the Chinese Academy of Engineering 2016
3. Award for Special Contribution in Development of the West Regions in China 2008 (China Association for Science and Technology)
4. National Excellent Worker Advanced in Science and Technology 2005
5. 3rd Youth Teacher of Higher Education Award Winner 2002 (China’s Ministry of Education)
6. China Youth Science and Technology Award Winner 2001
7. China’s National Youth Scholar of Outstanding Contribution 1999
8. Guangxi Excellent Professional Technician 1999
9. First Level Candidates for Guangxi “Ten, Hundred, Thousand Talents Project” 1998
10. Firstly Selected Candidates for National Hundred-Thousand-Ten Thousand Talents Project 1996
11. Special government allowances of the State Council 1996
12. Guangxi Excellent Expert 1996